Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 29Carcinoma, Non-Small-Cell Lung 28Breast Neoplasms 7Esophageal Neoplasms 5Ovarian Neoplasms 4Carcinoma, Renal Cell 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Salivary Gland Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Colonic Neoplasms 3Brain Neoplasms 3Adenocarcinoma of Lung 3Urinary Bladder Neoplasms 2Tongue Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Rectal Neoplasms 2Pleural Effusion, Malignant 2Pheochromocytoma 2Paraganglioma 2Oropharyngeal Neoplasms 2Neuroendocrine Tumors 2Nasopharyngeal Neoplasms 2Mouth Neoplasms 2Mesothelioma 2Melanoma 2Laryngeal Neoplasms 2

Interventions

durvalumab 2alfatide II 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-Small Cell Lung Cancer NSCLC × Fluorodeoxyglucose F18 × Thoracic × Clear all
NCT06416852 2024-05-16

Clinical Study of 18F-Alfatide Injection PET/CT

Yantai LNC Biotechnology Singapore PTE. LTD.

Phase 3 Not yet recruiting
428 enrolled
Thoracic

Non-Small Cell Lung Cancer NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡